Alaunos Therapeutics Touts Early Clinical Response For Its Cancer Cell Therapy
Alaunos Therapeutics Inc (NASDAQ:TCRT) announced early clinical findings from its ongoing TCR-T Library Phase 1/2 trial. “We are excited to announce…
Ironwood Shares Positive Top-line Data From Late-Stage Functional Constipation Candidate Study In Patients Aged 6-17 Years
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced positive top-line data from its Phase 3 clinical trial evaluating LINZESS (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional constipation (FC).
Emergent Shares Decline Following Commencement Of Initial-Stage Lassa Virus Vaccine Candidate Study
Emergent BioSolutions (NYSE: EBS) has dosed first patient in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV in healthy subjects.
EBS-LASV is a recombinant VSV-vectored Lassa virus vaccine candidate being evaluated for prevention of disease caused by Lassa virus infection.
MannKind Shares Fall After Completing Initial Stage Lung Disease Study
MannKind Corporation (NASDAQ: MNKD) has successfully completed a Phase 1 study of clofazimine inhalation suspension (MNKD 101), an inhalation treatment option for nontuberculous mycobacterial (NTM) lung disease.
Iveric Bio Shares Shoot Higher Following Positive Top-line Data From Late-Stage Geographic Atrophy Study
Iveric Bio (NASDAQ: ISEE) announced positive topline results from the second Phase 3 clinical trial of Zimura (avacincaptad pegol) for the treatment of geographic atrophy (GA).
Ironwood’s Constipation Drug Shows Efficacy In Pediatric Patients
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) announced topline data from a Phase 3 trial evaluating Linzess (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional constipation.
IDEAYA Shares Climb As Initial Stage Uveal Melanoma Study Kick-off In Australia
IDEAYA Biosciences (NASDAQ: IDYA) has initiated Investigator Sponsored Trial to evaluate darovasertib as monotherapy in neo-adjuvant and adjuvant settings in primary, non-metastatic uveal melanoma (UM) patients.
Top Financial Stories Tuesday, September 6: Focus on iPhone 14 Event, OPEC+ Plans Mild Production Cut, Netflix Says No To Crypto Ads And More…
Reuters
EQT Corp Close To Buying THQ Appalachia
European Commission Says No To Illumina-Grail Deal – What’s Next?
The European Commission has prohibited Illumina Inc’s (NASDAQ:ILMN) acquisition of GRAIL. The company is reviewing the Commission’s order and intends to…
Sanofi-Regeneron’s Flagship Drug Shows Consistent Efficacy, Safety Profile At Two Years For Asthma In Kids
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) announced results from a Phase 3 open-label extension trial of Dupixent (dupilumab) as maintenance therapy…